(Q39127374)
Statements
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity (English)
Laurence H Patterson
Sandra Travica
Inger Johansson
Mark Sutherland
Lina Elsalem
Nicola Illingworth
Tristan Reuillon
Magnus Ingelman-Sundberg